Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5483
Abstract: The phase 3 CLEAR study demonstrated statistically significantly improved efficacy with lenvatinib plus pembrolizumab versus sunitinib, including progression‐free survival and overall survival, in patients with previously untreated advanced renal cell carcinoma. This subset analysis investigated… read more here.
Keywords: sunitinib; plus pembrolizumab; pembrolizumab versus; lenvatinib plus ... See more keywords
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2024 at "Investigational New Drugs"
DOI: 10.1007/s10637-024-01461-z
Abstract: Combining a checkpoint inhibitor with an inhibitor of extracellular signal-regulated kinase (ERK) may result in synergistic antitumor activity. We evaluated MK-8353, an ERK1 and ERK2 inhibitor, plus pembrolizumab in a phase 1b study in patients… read more here.
Keywords: arm; solid tumors; plus pembrolizumab; inhibitor ... See more keywords
Induction chemotherapy backbone in frail patients with advanced NSCLC treated with chemotherapy plus pembrolizumab: a single institution retrospective audit of dose intensities from modified regimens.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Chemotherapy"
DOI: 10.1080/1120009x.2024.2388474
Abstract: Abstract Guidelines historically recommended mono-chemotherapy for the 1st line treatment of elderly patients with non-small cell lung cancer (NSCLC) and poor performance status (PS). Nowadays, there is no clear indication whether chemo-immunotherapy (chemo-IO) combinations can… read more here.
Keywords: modified regimens; induction chemotherapy; chemotherapy; plus pembrolizumab ... See more keywords
Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study.
Sign Up to like & getrecommendations! Published in 2025 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyaf182
Abstract: INTRODUCTION Enfortumab vedotin plus pembrolizumab (EVP) has shown promising efficacy in locally advanced or metastatic urothelial carcinoma (la/mUC), but real-world data in Japanese patients are limited. We assessed the safety and early efficacy of EVP,… read more here.
Keywords: metastatic urothelial; enfortumab vedotin; vedotin plus; advanced metastatic ... See more keywords
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003569
Abstract: Background The combination of antiangiogenic agents with immune checkpoint inhibitors could potentially overcome immune suppression driven by tumor angiogenesis. We report results from a phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced… read more here.
Keywords: aflibercept plus; ziv; ziv aflibercept; plus pembrolizumab ... See more keywords
Abstract CT108: A phase 1b study of abemaciclib in combination with pembrolizumab for patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) (NCT02779751): Preliminary results
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-ct108
Abstract: Background: Abemaciclib is an orally administered, selective small molecule cyclin-dependent kinase (CDK) 4 and 6 inhibitor, approved to treat HR+, HER2- mBC pts on a continuous twice daily dosing schedule as monotherapy or in combination… read more here.
Keywords: combination; plus pembrolizumab; mbc; cancer ... See more keywords
Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs17-p1-09-01
Abstract: Background: Abemaciclib is a selective and potent small molecule inhibitor of CDK4 and 6, with evidence of single-agent antitumor activity, and a safety profile that enables dosing on a continuous schedule. Abemaciclib demonstrated anti-tumor activity… read more here.
Keywords: plus pembrolizumab; abemaciclib plus; study; cancer ... See more keywords
Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma
Sign Up to like & getrecommendations! Published in 2024 at "Liver Cancer"
DOI: 10.1159/000540290
Abstract: Abstract Introduction: Fibrolamellar carcinoma (FLC) displays upregulation of several oncogenes, including HER2, and multiple immune-suppressive mechanisms. We investigated the efficacy and safety of the pan-HER tyrosine kinase inhibitor neratinib as monotherapy (SUMMIT phase 2 basket… read more here.
Keywords: received neratinib; summit; immune checkpoint; plus pembrolizumab ... See more keywords
First-line systemic therapy in patients with metastatic or locally advanced urothelial carcinoma: a systematic review and network meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2025 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359251357527
Abstract: Background: The emergence of immune checkpoint inhibitors and antibody–drug conjugates has revolutionized the first-line treatment landscape for locally advanced or metastatic urothelial carcinoma (la/mUC). However, the optimal treatment strategy remains uncertain. Objectives: This network meta-analysis… read more here.
Keywords: treatment; analysis; first line; plus pembrolizumab ... See more keywords
Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007779
Abstract: Key Points • The best response rates were observed with pembrolizumab before tisagenlecleucel; however, definitive conclusions cannot be made.• Pembrolizumab did not augment the cellular expansion of tisagenlecleucel but delayed peak expansion in the day… read more here.
Keywords: tisagenlecleucel plus; pembrolizumab patients; plus pembrolizumab; safety efficacy ... See more keywords
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco-25-00748
Abstract: PURPOSE The phase III randomized open-label LEAP-015 study (ClinicalTrials.gov identifier: NCT04662710) evaluated first-line lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy for advanced metastatic gastroesophageal adenocarcinoma. METHODS Eligible participants 18 years and older with untreated human… read more here.
Keywords: pembrolizumab chemotherapy; lenvatinib plus; chemotherapy; plus pembrolizumab ... See more keywords